Compare Sirius XM Holdings Inc (SIRI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sirius XM Holdings Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Sirius XM Holdings Inc trades at $26.8 (market cap $8.87B), while Vertex Pharmaceuticals Incorporated trades at $508.7 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 14.4× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays a 4.1% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sirius XM Holdings Inc for 102 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SIRI | VRTX | |
|---|---|---|
Market Cap | $8.87B | $127.55B |
Volume | 4,324,672 | 1,487,944 |
Sector | Media | Health |
52-Week High | $32.59 | $557.96 |
52-Week Low | $19.92 | $407.37 |
Typical Hold Time | 102 Days | 120 Days |
Enterprise Value | $18.16B | $121.68B |
Dividend Yield | 4.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SIRI trades at $25.95, down 1.56% with a bearish technical signal. The company shows mixed fundamentals with a P/E of 10.57 and P/B of 0.75 indicating potential undervaluation, but recent earnings misses and a significant net loss in 2024 raise concerns. Positive cash flow growth and a 62.5% analyst buy rating provide support, while the YouTube partnership offers growth potential.
The stock presents a value opportunity with upside to the $34.43 consensus target, but faces execution risks from subscription pressure and high debt. Recent institutional buying and management's focus on cash flow growth are positive catalysts, though technical weakness and competitive threats warrant caution for near-term investors.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
